Literature DB >> 30858017

Prolonged activation of CXCR4 hampers the release-regulating activity of presynaptic NMDA receptors in rat hippocampal synaptosomes.

Guendalina Olivero1, Francesca Cisani1, Matteo Vergassola1, Anna Pittaluga2.   

Abstract

We investigated the impact of the prolonged exposure of rat hippocampal synaptosomes to CXCL12 (3 nM) on the NMDA-mediated release of [3H]D-aspartate ([3H]D-Asp) or [3H]noradrenaline ([3H]NA). Synaptosomes were stimulated twice with NMDA/CXCL12 and the amount of the NMDA-evoked tritium release (S1 and S2) quantified to calculate the S2/S1 ratio. The S2/S1 ratio for both transmitters was drastically decreased by 3 nM CXCL12 between the two stimuli (CXCL12-treated synaptosomes) in a AMD3100-sensitive manner. The phosphorylation of the GluN1 subunit in Ser 896 was reduced in CXCL12-treated synaptosomes, while the overall amount of GluN1 and GluN2B proteins as well as the GluN2B insertion in synaptosomal plasmamembranes were unchanged. We conclude that the CXCR4/NMDA cross-talk is dynamically regulated by the time of activation of the CXCR4s. Our results unveil a functional cross-talk that might account for the severe impairments of central transmission that develop in pathological conditions characterized by CXCL12 overproduction.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  CXCL12; CXCR4; Glutamate; NMDA receptor; Noradrenaline; Phospho-GluN1 (Ser896)

Mesh:

Substances:

Year:  2019        PMID: 30858017     DOI: 10.1016/j.neuint.2019.03.003

Source DB:  PubMed          Journal:  Neurochem Int        ISSN: 0197-0186            Impact factor:   3.921


  2 in total

1.  Synaptosomes and Metamodulation of Receptors.

Authors:  Anna Pittaluga; Mario Marchi
Journal:  Methods Mol Biol       Date:  2022

Review 2.  Presynaptic Release-regulating Metabotropic Glutamate Receptors: An Update.

Authors:  Guendalina Olivero; Matteo Vergassola; Francesca Cisani; Alessandra Roggeri; Anna Pittaluga
Journal:  Curr Neuropharmacol       Date:  2020       Impact factor: 7.363

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.